Follow-The-Filings

Security

ALGS

Aligos Therapeutics Inc. · COM NEW

Equity holders as of 2026 Q1 (each manager’s latest book)

6 owners 1 new max 0.0% (Marshall Wace - Marshall ...)

grid → activity →
owners 6
max % 0.0%
tracked value $6M
qoq N 1 A 3 R 1

holders

sorted by % of portfolio · long equity only

manager % port activity shares value history
Marshall Wace - Marshall Wace, LLP 2026 Q1 0.0% Reduce 0.00 pp 267,135 $2M hist
Vanguard Group Inc. 2025 Q4 stale 0.0% Add 0.00 pp 200,395 $2M hist
Two Sigma Investments, LP 2025 Q4 stale 0.0% Exit 0.00 pp 80,649 $752 hist
Renaissance Technologies LLC 2026 Q1 0.0% Add 0.00 pp 100,450 $746 hist
Ken Griffin - Citadel Advisors LLC 2026 Q1 0.0% Add 0.00 pp 54,311 $404 hist
D. E. Shaw & Co., Inc. 2026 Q1 0.0% New 0.0% 10,978 $82 hist

6 current · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $6.19M $3.61M $2.19M
Gross profit — — —
Gross margin — — —
Net income -$87.68M -$131.21M -$24.19M
Net margin * -1416.2% -3633.6% -1106.7%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $141.08M $62.14M $82.86M
Total non-current assets * $10.44M $7.95M $5.67M
Total assets $151.53M $70.09M $88.53M
Total current liabilities $23.91M $21.74M $21.23M
Total non-current liabilities * $35.54M $77.33M $13.76M
Total equity $92.08M -$28.97M $53.54M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$79M -$80.74M -$82.5M
Cash from investing $44.98M -$18.28M -$37.83M
Cash from financing $88.33M $355,000 $101.64M
Net change in cash * $54.31M -$98.67M -$18.69M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders